Showing results (61-70 of 68) with videos related to

Sort By:
Pageof 7
You have reached the last page of results.This site can display upto 68 results.
Molecular Oncology|January 28, 2014
TP53 mutation-correlated genes predict the risk of tumor relapse and identify MPS1 as a potential therapeutic kinase in TP53-mutated breast cancersBalázs Győrffy, Giulia Bottai, Jacqueline Lehmann-Che, et al.
Journal of the National Cancer Institute|December 31, 2010
Gene pathways associated with prognosis and chemotherapy sensitivity in molecular subtypes of breast cancerTakayuki Iwamoto, Giampaolo Bianchini, Daniel Booser, et al.
Breast Cancer Research : BCR|September 25, 2013
Proliferation and estrogen signaling can distinguish patients at risk for early versus late relapse among estrogen receptor positive breast cancersGiampaolo Bianchini, Lajos Pusztai, Thomas Karn, et al.
Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|August 29, 2021
Phase 2 Study of Dabrafenib Plus Trametinib in Patients With BRAF V600E-Mutant Metastatic NSCLC: Updated 5-Year Survival Rates and Genomic AnalysisDavid Planchard, Benjamin Besse, Harry J M Groen, et al.
NPJ Breast Cancer|July 20, 2017
AXL-associated tumor inflammation as a poor prognostic signature in chemotherapy-treated triple-negative breast cancer patientsGiulia Bottai, Carlotta Raschioni, Borbála Székely, et al.
The Journal of Clinical Endocrinology and Metabolism|January 19, 2006
Missense mutation in the transcription factor NKX2-5: a novel molecular event in the pathogenesis of thyroid dysgenesisMonica Dentice, Viviana Cordeddu, Annamaria Rosica, et al.
Breast Cancer Research and Treatment|April 28, 2012
Mutation profiling identifies numerous rare drug targets and distinct mutation patterns in different clinical subtypes of breast cancersLibero Santarpia, Yuan Qi, Katherine Stemke-Hale, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 10, 2025
HER2CLIMB-05: A Phase 3 Study of Tucatinib Versus Placebo in Combination with Trastuzumab and Pertuzumab as First-line Maintenance Therapy for HER2+ Metastatic Breast CancerVeronique Dieras, Giuseppe Curigliano, Miguel Martin, et al.
Pageof 7